The city of Scottsdale, Arizona, currently has 9 active clinical trials seeking participants for Parkinson's Disease research studies.
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
06/13/2024
Locations: Pd0060 50590, Scottsdale, Arizona
Conditions: Parkinson Disease
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
06/04/2024
Locations: Movement Disorders Center of Arizona, LLC, Scottsdale, Arizona
Conditions: Parkinson's Disease
STEM-Parkinson's Disease
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Movement Disorder Center of Arizona, Scottsdale, Arizona
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
AMX0035 and Progressive Supranuclear Palsy
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/31/2024
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Recruiting
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tas... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
04/29/2024
Locations: Movement Disorders Center of Arizona, Scottsdale, Arizona
Conditions: Parkinson Disease, Tremor
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
All
Ages:
30 years and above
Trial Updated:
12/13/2023
Locations: Mayo Foundation for Medical Education and Research, Scottsdale, Arizona
Conditions: Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Scottsdale, Arizona
Conditions: Parkinson Disease
Noninterventional Study Evaluating Parkinson's Disease Diary Use
Recruiting
This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
Gender:
All
Ages:
Between 39 years and 70 years
Trial Updated:
09/12/2023
Locations: Mayo Clinic Neurology, Scottsdale, Arizona
Conditions: Parkinson's Disease
Trial of Parkinson's And Zoledronic Acid
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies